comparemela.com

Latest Breaking News On - Kazuko matsuda - Page 3 : comparemela.com

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

LA JOLLA, Calif., Jan. 17, 2024 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange , today announced it has.

China
Tokyo
Japan
Chinese
Geoff-obrien
Kazuko-matsuda
Chinese-patent-office
Medicinova-inc
Nasdaq
Exchange-commission
Standard-market
Tokyo-stock-exchange

Medicinova (MNOV) Granted Patent Covering MN-166

Medicinova (MNOV) Granted Patent Covering MN-166
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China
Tokyo
Japan
Chinese
Kazuko-matsuda
Chinese-patent-office
Nasdaq
Medicinova-inc
Standard-market
Tokyo-stock-exchange
Code-number
Chief-medical-officer

Ibudilast plus interferon-beta to get European patent for MS

Ibudilast plus interferon-beta to get European patent for MS
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Kazuko-matsuda

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Tokyo
Japan
Geoff-obrien
Kazuko-matsuda
European-patent-office
Medicinova-inc
Exchange-commission
Trademark-office
Nasdaq
Standard-market
Tokyo-stock-exchange
Code-number

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Tokyo
Japan
Geoff-obrien
Kazuko-matsuda
Medicinova-inc
Trademark-office
Nasdaq
Exchange-commission
European-patent-office
Nova-receives
New-patent-covering
Standard-market
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.